ClinicalTrials.gg
Active, not recruitingNCT07943182Updated Nov 17, 2026

Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients

An observational study in Cardiogenic Shock, Heart Failure and Acute Decompensated Heart Failure (ADHF), sponsored by Abiomed Inc.. Active, not recruiting at 24 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.

Planned enrollment
15th of 25
60 · median 124
Started
2024
with 5 others
Observational
25 of 50
9 open now
Primary completion
2027-12
later than 12 of 22 live
Registered
50th of 50
by date
Lead sponsor
6 of 50
Abiomed Inc.

Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 15th largest by planned enrollment of the 25 observational ones that give a count, is one of 6 that started in 2024, is one of 25 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 50th registered.

Shock, Cardiogenic

296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Shock, Cardiogenic with a site in United States, or all of them as a file.
02

Study summary

This post-approval study will evaluate the real-world safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist heart pumps in pediatric patients with cardiogenic shock or severe heart failure requiring temporary mechanical circulatory support.

The study will collect data from children and young adults younger than 22 years of age who receive an Impella device as part of their routine clinical care at hospitals participating in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry.

The primary objective is to assess survival at the time the Impella device is removed. Information collected during the patient's hospitalization, including clinical outcomes and adverse events, will be used to further evaluate the performance of these commercially approved devices in the pediatric population.

Read the detailed description

Cardiogenic shock and severe heart failure are associated with substantial morbidity and mortality in pediatric patients. Timely restoration of adequate circulation is critical to maintain organ perfusion, support recovery of cardiac function, and facilitate transition to advanced therapies when needed.

Pediatric patients often face unique challenges related to disease complexity, body size, and limitations in available treatment options. The Impella family of left ventricular support devices provides temporary mechanical circulatory support by unloading the ventricle and increasing cardiac output, and has been used in pediatric patients with cardiogenic shock and advanced heart failure. Published reports and analyses of real-world clinical experience suggest that Impella support may provide effective short-term hemodynamic stabilization and serve as a bridge to myocardial recovery, durable mechanical support, heart transplantation, or re-transplantation.

This post-approval study is being conducted to further evaluate the continued safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist devices in pediatric patients receiving temporary left ventricular mechanical circulatory support. The study leverages data collected through the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), a multicenter registry that captures real-world clinical information on pediatric patients with heart failure and advanced cardiac therapies.

Clinical, procedural, and outcome data collected during routine care will be analyzed to characterize patient outcomes associated with Impella support in contemporary clinical practice. Information obtained through the study will contribute to the understanding of device performance, safety events, and clinical outcomes in pediatric patients treated with commercially available Impella devices. The results are intended to support ongoing evaluation of these devices in the pediatric population and to provide additional real-world evidence regarding their use in patients requiring temporary hemodynamic support.

03

Conditions studied

  • Cardiogenic Shock
  • Heart Failure
  • Acute Decompensated Heart Failure (ADHF)
  • Cardiomyopathy
  • Myocarditis

Keywords

  • Cardiogenic Shock
  • Heart Failure
  • Pediatric Heart Failure
  • Impella
  • Impella CP with SmartAssist
  • Impella 5.5 with SmartAssist
  • Mechanical Circulatory Support
  • Temporary Ventricular Assist Device
  • Bridge to Transplant
  • Real-World Evidence
  • Pediatric
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients (\< 22 years old) who receive left ventricular hemodynamic support with a left/systemic ventricular Impella device (Impella CPSA or 5.5).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient received a left/systemic ventricular Impella device: Impella CPSA and/or Impella 5.5
  2. Age \< 22 years

Exclusion criteria

Exclusion Criteria:

1. Age ≥ 22 years

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Pediatric Patients Receiving Impella Support

    Pediatric patients younger than 22 years of age who receive a commercially approved left ventricular Impella device (Impella CP with SmartAssist and/or Impella 5.5 with SmartAssist) as part of routine clinical care and are enrolled through the ACTION (Advanced Cardiac Therapies Improving Outcomes Network) registry.

    Device: Impella CP with SmartAssist · Device: Impella 5.5 with SmartAssist

Interventions

  • DeviceImpella CP with SmartAssist

    Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.

    Also known as: Impella Device, Impella Left Ventricular Support Systems

  • DeviceImpella 5.5 with SmartAssist

    Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.

    Also known as: Impella Device, Impella Left Ventricular Support Systems

06

What researchers measure

Primary outcomes

  1. Survival rate at Impella Device Explant

    The primary endpoint is to evaluate the survival rate at Impella device explant. Impella device explant due to unacceptable prognosis will not count towards successful survival to explant.

    Time frame: From date of Impella implant until Impella device explant or date of death from any cause, whichever is first. The duration of time allotted until explant is not pre-specified in the study protocol but is estimated up to 12 months

07

Study locations

24 sites
08

References and documents

Publications

  • Dimas VV, Murthy R, Guleserian KJ. Utilization of the Impella 2.5 micro-axial pump in children for acute circulatory support. Catheter Cardiovasc Interv. 2014 Feb;83(2):261-2. doi: 10.1002/ccd.25042. Epub 2013 Jul 23. PubMed 23729308 ↗
  • Perri G, Trezzi M, Formigari R, Adorisio R, Filippelli S, Brancaccio G, Galletti L, Amodeo A. Use of Transcarotid IMPELLA 2.5 Axial-Flow Pump Device for Left Ventricle Unloading During VA-ECMO Support in Pediatric Acute Heart Failure. World J Pediatr Congenit Heart Surg. 2021 Jul;12(4):542-546. doi: 10.1177/21501351211017866. PubMed 34278855 ↗
  • Glazier JJ, Kaki A. The Impella Device: Historical Background, Clinical Applications and Future Directions. Int J Angiol. 2019 Jun;28(2):118-123. doi: 10.1055/s-0038-1676369. Epub 2018 Dec 20. PubMed 31384109 ↗
  • Kawashima D, Gojo S, Nishimura T, Itoda Y, Kitahori K, Motomura N, Morota T, Murakami A, Takamoto S, Kyo S, Ono M. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J. 2011 May-Jun;57(3):169-76. doi: 10.1097/MAT.0b013e31820e121c. PubMed 21317769 ↗
  • Brissaud O, Botte A, Cambonie G, Dauger S, de Saint Blanquat L, Durand P, Gournay V, Guillet E, Laux D, Leclerc F, Mauriat P, Boulain T, Kuteifan K. Experts' recommendations for the management of cardiogenic shock in children. Ann Intensive Care. 2016 Dec;6(1):14. doi: 10.1186/s13613-016-0111-2. Epub 2016 Feb 16. PubMed 26879087 ↗

Individual participant data

Plan to share: No — Data is simply provided to FDA and intent to publish is not yet determined by Sponsor.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 84 observational studies under Shock, Cardiogenic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartActual
Dec 3, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943182
Lead sponsor
Abiomed Inc.
Collaborators
Johnson & Johnson
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 3, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion